AmgenvsKura Oncology

AMGN and KURA stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$435.64

Value $235B

-0.72%
AMGN's page

Amgen (AMGN) has a market value of $235B and Kura Oncology (KURA) $610M. Over the last year, with dividends, AMGN moved +31.5% and KURA -39.0%. Dividend yield: AMGN 2.31%, KURA none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$235B

    KURA$610M

    AMGN is 385 times KURA

  • Revenue, 12 months

    AMGN$38.9B

    KURA$79M

    AMGN is 490 times KURA

  • Net income, 12 months

    AMGN$9.4B

    KURA-$293M

  • Operating margin

    AMGN32.4%

    KURA-394.3%

    426.7 points apart

  • ROIC

    AMGN16.2%

    KURA-192.2%

    208.4 points apart

  • P/E

    AMGN25.0

    KURA–

  • Dividend yield

    AMGN2.3%

    KURA0.0%

    2.3 points apart

  • 5-year return

    AMGN+146.3%

    KURA-59.3%

    205.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+146.4%

KURA-59.3%

10020020222023202420252026
Returns by period
PeriodAMGNWith dividendsKURAWith dividends
1 year since November 19, 2025+31.5%Price +27.2%-39.0%Price -39.0%
3 years since November 20, 2023+79.2%+21.5% a yearPrice +64.2%-27.6%-10.2% a yearPrice -27.6%
5 years since November 19, 2021+146.3%+19.8% a yearPrice +111.4%-59.3%-16.5% a yearPrice -59.3%
10 years since November 21, 2016+302.7%+14.9% a yearPrice +199.3%+25.6%+2.3% a yearPrice +25.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenKURAKura Oncology

Valuation

AMGNKURA
Valuation
Price$435.64$6.91
Market value$235B$610M
Enterprise value (EV)$276B–
P/E25.0–
P/E, 5-year median23.0–
P/B16.434.0
EV/EBIT21.9–
Free cash flow yield4.1%–

Results and growth

AMGNKURA
Results and growth
Revenue, 12 months$38.9B$79M
Net income, 12 months$9.4B-$293M
Free cash flow, 12 months$9.6B-$89M
Earnings per share, 12 months$17.25-$3.30
Revenue growth, year on year10.0%25.2%
Revenue growth a year, past+7.6%over 5 years–
EPS growth a year, past+2.9%over 5 years–

Margins and returns on capital

AMGNKURA
Margins and returns on capital
Gross margin70.9%–
Operating margin32.4%-394.3%
Net margin24.1%-369.3%
ROIC16.2%-192.2%
ROE87.8%-247.8%

Balance sheet

AMGNKURA
Balance sheet
Cash$13.2B$492M
Total debt$54.0B–
Net debt / EBITDA2.3–
Interest cover4.8×-227.1×

Dividends and buybacks

AMGNKURA
Dividends and buybacks
Dividend yield2.3%–
Dividend per share, 12 months$10.08–
Dividend growth a year, past+8.1%over 5 years–
Buyback yield––
Shareholder yield2.3%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or KURA

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or Kura Oncology?

By market value, Amgen ($235B) is about 384.8 times Kura Oncology ($610M), at today's prices.

How did AMGN and KURA stock do over the last 10 years?

Since November 21, 2016, AMGN's price moved +199.3% and KURA's +25.6%. With dividends: AMGN +302.7% (+14.9% a year), KURA +25.6% (+2.3% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or KURA?

The dividend yield at today's price is 2.31% for Amgen and none for Kura Oncology. Over the last twelve months they paid $10.08 and – per share.

Which has the higher profit margins, Amgen or Kura Oncology?

Over the last twelve months, the net margin was 24.1% for Amgen and -369.3% for Kura Oncology, and the operating margin 32.4% and -394.3%. Revenue was $38.9B and $79M.

Which is the better investment, Amgen or Kura Oncology?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.